{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T07:00:50Z","timestamp":1780124450051,"version":"3.54.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.semarthrit.2025.152768","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T20:13:00Z","timestamp":1749154380000},"page":"152768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Assessment of triple antiphospholipid antibody-positive patients based on clinical and laboratory domains of 2023 ACR\/EULAR antiphospholipid syndrome classification criteria"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9017-8483","authenticated-orcid":false,"given":"Reyhan Kose","family":"Cobanoglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doruk","family":"Erkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.semarthrit.2025.152768_bib0001","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152768_bib0002","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1160\/TH04-12-0839","article-title":"Antibody profiles for the diagnosis of antiphospholipid syndrome","volume":"93","author":"Pengo","year":"2005","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152768_bib0003","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1136\/ard.2010.145177","article-title":"Risk scale for the diagnosis of antiphospholipid syndrome","volume":"70","author":"Sciascia","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"10.1016\/j.semarthrit.2025.152768_bib0004","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1177\/0961203314545410","article-title":"Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study","volume":"23","author":"Mustonen","year":"2014","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152768_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002881","article-title":"Identifying high-risk profile in primary antiphospholipid syndrome through cluster analysis: French multicentric cohort study","volume":"9","author":"Guedon","year":"2023","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152768_bib0006","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"17","key":"10.1016\/j.semarthrit.2025.152768_bib0007","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2011-03-340232","article-title":"Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study","volume":"118","author":"Pengo","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152768_bib0008","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/0961203316657433","article-title":"Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity","volume":"26","author":"Yelnik","year":"2017","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152768_bib0009","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0961203317692432","article-title":"Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile","volume":"26","author":"Latino","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2025.152768_bib0010","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.3389\/fimmu.2019.01948","article-title":"Triple antiphospholipid (aPL) antibodies positivity is associated with pregnancy complications in aPL carriers: A multicenter study on 62 pregnancies","volume":"10","author":"Lazzaroni","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152768_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002534","article-title":"Triple positive profile in antiphospholipid syndrome: prognosis, relapse and management from a retrospective multicentre study","volume":"9","author":"Laurent","year":"2023","journal-title":"RMD Open"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152768_bib0012","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1055\/a-1344-4271","article-title":"Clinical relevance of isolated Lupus anticoagulant positivity in patients with thrombotic antiphospholipid syndrome","volume":"121","author":"Yin","year":"2021","journal-title":"Thromb Haemost"},{"issue":"22","key":"10.1016\/j.semarthrit.2025.152768_bib0013","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2014-11-611129","article-title":"Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS)","volume":"125","author":"Gebhart","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152768_bib0014","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152768_bib0015","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood-2007-01-066043","article-title":"Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study","volume":"110","author":"Galli","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152768_bib0016","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1538-7836.2008.02862.x","article-title":"Invitation to a debate on the serological criteria that define the antiphospholipid syndrome","volume":"6","author":"Galli","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152768_bib0017","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1538-7836.2008.02965.x","article-title":"A contribution to the debate on the laboratory criteria that define the antiphospholipid syndrome","volume":"6","author":"Pengo","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152768_bib0018","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/jth.13379","article-title":"IgG\/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis","volume":"14","author":"Kelchtermans","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152768_bib0019","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/jth.14633","article-title":"The (non-) sense of detecting anti-cardiolipin and anti-\u03b22glycoprotein I IgM antibodies in the antiphospholipid syndrome","volume":"18","author":"Chayoua","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152768_bib0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152768_bib0021","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.thromres.2015.08.019","article-title":"The clinical relevance of the IgM isotype of antiphospholipid antibodies in the vascular antiphospholipid syndrome","volume":"136","author":"Del Ross","year":"2015","journal-title":"Thromb Res"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152768_bib0022","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1161\/STROKEAHA.118.023021","article-title":"Antiphospholipid syndrome with isolated isotype M anticardiolipin and\/or anti-B2GPI antibody is associated with stroke","volume":"49","author":"Urbanski","year":"2018","journal-title":"Stroke"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152768_bib0023","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR Antiphospholipid Syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152768_bib0024","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152768_bib0025","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/acr.24468","article-title":"Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION International Clinical Database and Repository","volume":"74","author":"Sevim","year":"2022","journal-title":"Arthritis Care Res (Hob)"},{"issue":"SI","key":"10.1016\/j.semarthrit.2025.152768_bib0026","doi-asserted-by":"crossref","first-page":"SI24","DOI":"10.1093\/rheumatology\/kead571","article-title":"Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations","volume":"63","author":"Gaspar","year":"2024","journal-title":"Rheumatol (Oxf.)"},{"issue":"13","key":"10.1016\/j.semarthrit.2025.152768_bib0027","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1177\/0961203319882506","article-title":"Clinical characteristics and risk factors of microvascular involvement in primary antiphospholipid syndrome: a longitudinal single-center study in China","volume":"28","author":"Sun","year":"2019","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152768_bib0028","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s40744-023-00610-9","article-title":"Serum Calprotectin as a potential predictor of microvascular manifestations in patients with antiphospholipid syndrome","volume":"10","author":"Zhao","year":"2023","journal-title":"Rheumatol Ther"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152768_bib0029","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jth.14261","article-title":"Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-\u03b22glycoprotein I antibody detection assays","volume":"16","author":"Chayoua","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152768_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2023.100147","article-title":"Associations among antiphospholipid antibody types, isotypes, and titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study","volume":"103","author":"Gkrouzman","year":"2023","journal-title":"Lab Invest"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152768_bib0031","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.jtha.2023.04.001","article-title":"Added value of antiphosphatidylserine\/prothrombin antibodies in the workup of obstetric antiphospholipid syndrome: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"21","author":"Vandevelde","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.semarthrit.2025.152768_bib0032","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.thromres.2022.04.021","article-title":"Prevalence of aPhosphatidylserine\/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: A systematic review and meta-analysis","volume":"214","author":"Zhu","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.semarthrit.2025.152768_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1459842","article-title":"Cell-bound complement activation products in antiphospholipid antibody-positive patients without other systemic autoimmune rheumatic diseases","volume":"15","author":"Erkan","year":"2024","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152768_bib0034","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1136\/ard-2023-225042","article-title":"Correspondence on '2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"83","author":"Miro-Mur","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152768_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103237","article-title":"Assessment of the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria in a Chinese cohort: impact on clinical practice","volume":"146","author":"Yang","year":"2024","journal-title":"J Autoimmun"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:00:52Z","timestamp":1780120852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225001398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":35,"alternative-id":["S0049017225001398"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152768","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of triple antiphospholipid antibody-positive patients based on clinical and laboratory domains of 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152768","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152768"}}